175 related articles for article (PubMed ID: 29908418)
1. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vulaj V; Perissinotti AJ; Uebel JR; Nachar VR; Scappaticci GB; Crouch A; Bixby DL; Burke PW; Maillard I; Talpaz M; Marini BL
Leuk Res; 2018 Jul; 70():91-96. PubMed ID: 29908418
[TBL] [Abstract][Full Text] [Related]
2. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
[TBL] [Abstract][Full Text] [Related]
4. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
6. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
8. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
14. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
15. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
Talati C; Goldberg AD; Przespolewski A; Chan O; Ali NA; Kim J; Famulare C; Sallman D; Padron E; Kuykendall A; Lancet JE; Wang E; Tallman MS; Komrokji R; Sweet K
Leuk Res; 2020 Jun; 93():106367. PubMed ID: 32408060
[TBL] [Abstract][Full Text] [Related]
16. FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
Shaikh MR; Singh B; Halder R; Singh R; Shaikh MR; Agarwal N; Bansal N; Ahmed R; Mirgh SP; Bhurani D
Leuk Res; 2023 Sep; 132():107346. PubMed ID: 37467566
[TBL] [Abstract][Full Text] [Related]
17. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Choi Y; Lee KH;
Eur J Haematol; 2016 Feb; 96(2):188-97. PubMed ID: 25891993
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
